The life sciences tools and services company said U.S.-China tariffs are expected to cut 2025 revenue by $400 million and adjusted operating income by $375 million.
The CDMO plans to build and expand small, medium, and large manufacturing facilities across Europe and the U.S. over the next three years to meet rising demand for peptides.
The CDMO, with 3,200 employees at 20 locations in the U.S., Europe and India, has a global footprint to help customers navigate their R&D and manufacturing challenges.
The company says it is investing in areas across the value chain to ensure its customers continue to enjoy the benefits of a global network with local access.
Despite Trump’s efforts to bring manufacturing back to the U.S., the threat of tariffs is accelerating an ongoing move to regional redundancy and capacity distribution.
The White House on Wednesday said pharmaceuticals are exempted from the reciprocal tariffs. Jefferies analysts called the impact on biopharma “minimal” at least for now.
Net profit for the first quarter of 2025 jumped to 375.6 billion South Korean won, while Plant 5 — the first facility at its Bio Campus II — became operational this month.
In the pharmaceutical industry, the pressure to produce high-quality products and remain competitive has never been greater. The rising costs of drug manufacturing and the increasing...
What’s next for pharma manufacturing in 2025? As the industry continues to respond to new scientific breakthroughs, supply chain pressures, and geopolitical tensions, the...
Pharmaceutical manufacturing operates in a high-stakes environment where regulatory compliance, product integrity, and operational uptime are non-negotiable. As the industry becomes...
